BMRN - Major Decision: Dennis Slamon Exercises Options Realizing $50K At Biomarin Pharmaceutical | Benzinga
Dennis Slamon, Board Member at Biomarin Pharmaceutical (NASDAQ:BMRN), reported a large exercise of company stock options on March 20, according to a new SEC filing.
What Happened: Disclosed in a Form 4 filing on Wednesday with the U.S. Securities and Exchange Commission, Slamon, Board Member at Biomarin Pharmaceutical, executed a strategic derivative sale. This involved exercising stock options for 10,000 shares of BMRN, resulting in a transaction value of $50,600.
During Thursday's morning session, Biomarin Pharmaceutical shares down by 0.0%, currently priced at $84.76. Considering the current price, Slamon's 10,000 shares have a total value of $50,600.
Delving into Biomarin Pharmaceutical's Background
BioMarin's focus is on rare-disease therapies. Genzyme (now part of Sanofi) markets Aldurazyme through its joint venture with BioMarin, and BioMarin markets Naglazyme, Vimizim, and Brineura independently. BioMarin also markets Kuvan and Palynziq to treat the rare metabolic disorder PKU. Voxzogo (vosoritide) was approved in achondroplasia in 2021. BioMarin's Roctavian (hemophilia A gene therapy) was approved in Europe in 2022 and in the US in 2023.
A Deep Dive into Biomarin Pharmaceutical's Financials
Positive Revenue Trend: Examining Biomarin Pharmaceutical's financials over 3 months reveals a positive narrative. The company achieved a noteworthy revenue growth rate of 20.22% as of 31 December, 2023, showcasing ...